Introduction
The biology behind many neuropsychiatric conditions remains elusive, but recent studies implicate immune dysregulation in some cases, particularly the presence of autoantibodies targeting neural tissue. Numerous studies have linked movement, behavior, and neuropsychiatric disorders to infections and the production of anti-neuronal autoantibodies (Kirvan 2003; Cox et al. 2013; anti-neuronal autoantibodies similar to those associated with Sydenham chorea have been linked to childhood obsessive-compulsive disorder (OCD) and/or tics (Kirvan 2003; Swedo 1994; Swedo et al. 1998; Swedo et al. 1997; Swedo et al. 1993; Swedo et al. 1989) . When symptom onset is abrupt, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) are two disorders used to describe these symptoms. The diagnostic criteria for PANS is defined as an abrupt onset of OCD or severely restricted food intake, and the presence of at least two of the following seven categories: (1) anxiety;
(2) emotional lability and/or depression; (3) irritability, aggression, and/or severely oppositional behaviors; (4) behavioral (developmental) regression; (5) deterioration in school performance (related to attention deficit hyperactivity disorder-like symptoms, memory deficits, cognitive changes); (6) sensory or motor abnormalities; (7) somatic signs and symptoms, including sleep disturbances, enuresis, or increased urinary frequency (Swedo et al. 1997; Chang et al. 2015) .
Since Sydenham chorea has a well-established biological mechanism connecting streptococcal infections with autoimmune-induced neuropsychiatric symptoms, it has been used as a biological model to better understand PANDAS and PANS (Cunningham 2012 (Cunningham , 2014 ). Central nervous system (CNS) autoimmune targets that were originally identified through multiple studies in patients with Sydenham chorea were applied to patients with PANDAS. Targets identified to overlap between Sydenham chorea and PANDAS were used to develop the Cunningham Panel, a set of blood tests utilized for measuring immune dysfunction, related to neuropsychiatric conditions associated with an infectious trigger. Journal Pre-proof stimulate calcium/calmodulin-dependent protein kinase II (CaMKII) activity in human neuronal cells. We briefly review the biological basis for the selection of these five assays below.
Biological Basis of Assays in the Cunningham Panel

Anti-Lysoganglioside GM1 Assay
Commercially available measurements of human group A streptococcal (GAS) antibodies (i.e., ASO and/or anti-DNase B antibodies) are sufficient for measuring GAS reactivity, but do not provide any relationship to GAS-related autoimmune reactivity and the CNS. Using human monoclonal antibodies derived from Sydenham chorea patients, Cunningham and Kirvan observed significant cross-reactivity against neurons in the human basal ganglia (Kirvan 2003) and against N-acetyl-beta Dglucosamine (GlcNAc), the major constituent of the GAS cell wall, a carbohydrate epitope. They observed strong cross-reactivity against the neuronal surface antigen lysoganglioside GM1 but not against other gangliosides (Kirvan 2003; Kirvan et al. 2007) . Lysoganglioside GM1 antigen also blocked binding of these autoantibodies to human caudate and putamen, demonstrating specific neural targets in the brain center known to be involved in movement disorders such as chorea, tics and stereotypies , whereas these serum autoantibodies receded to normal levels during convalescence. In addition, IgG derived from the serum or cerebrospinal fluid (CSF) of Sydenham chorea and PANDAS patients was found to target human caudate and putamen brain tissue, and this reaction could be inhibited by lysoganglioside GM1 ).
CaMKII Cell Stimulation Assay
Integrated into the Cunningham panel is the measurement of CaMKII activation which is mechanistically important since activation increases the activity of tyrosine hydrolase, an enzyme that produces dopamine, resulting in increased dopamine output, a key neurotransmitter involved in movement disorders. Both IgG from sera and CSF of PANDAS patients were found to signal activation of CaMKII in human neuronal cells . Supporting the specificity of GAS antibodies causing CaMKII activation, it was demonstrated that activation was blocked by streptococcal-associated GlcNAc or by depleting immunoglobulins from serum and CSF by affinity J o u r n a l P r e -p r o o f Journal Pre-proof column adsorption . Additional data showed that CaMKII was activated 202% above basal level in Sydenham chorea and PANDAS patients during the acute phase, whereas convalescent serum collected in the absence of chorea showed no significant increase in CaMKII activity (Kirvan 2003) . Finally, additional studies have shown that patient symptom improvement was associated with a reduction in CaMKII activation.
CaMKII is also involved in the regulation of N-methyl-D-aspartate (NMDA) receptor excitability via glutamate transmission (Hell 2014) which is being recognized in syndromes which include OCD, tics, and Tourette Syndrome (Marsili et al. 2017) , and being recognized as a treatment target in OCD (Laoutidis, Lekka, and Kioulos 2016) . Mutations in CAMK2A and CAMK2B, the genes that code for CaMKII, have been associated with intellectual disability (Kury et al. 2017 ) and ASD-related behaviors such as hyperactivity, social interaction deficits, and repetitive behaviors (Stephenson et al. 2017 ).
Other studies have linked CaMKII to the pathogenesis and symptoms in a variety of mental and neurological illnesses, including learning disorders, cognitive impairment, schizophrenia (Robison 2014; Kury et al. 2017) , ischemia, Alzheimer's disease (Ly and Song 2011; Ghosh and Giese 2015) , epilepsy (Zhang et al. 2014; Robison 2014 ) and Parkinson's disease (Zhang et al. 2014; Zaichick, McGrath, and Caraveo 2017).
Anti-Dopamine D1 and D2L Receptor
The inclusion of dopamine D1 and D2L receptors as targets arose from studies that demonstrated autoantibodies directed against dopamine D1 and D2L receptors correlated with various neuropsychiatric symptoms (Ben-Pazi, Stoner, and Cunningham 2013) . Two types of anti-neuronal human antibodies against the dopamine receptors induced an increase in dopamine neurotransmitter release ). D1 and D2L receptors antibodies were elevated in patients with Sydenham chorea and PANDAS compared to controls (Kirvan 2003; Kirvan et al. 2007; J o u r n a l P r e -p r o o f al. 2013; Cox et al. 2015; Cunningham and Cox 2016) , and are likely important in pathogenesis of neuropsychiatric diseases associated with infection (Singer et al. 2015; Brimberg et al. 2012 ).
(Insert Figure 1 Here)
Anti-Tubulin
Human monoclonal antibodies derived from patients with Sydenham chorea, reacted with human caudate and putamen brain sections and reactivity was blocked by anti-tubulin monoclonal antibodies. The reactive epitope of these brain proteins was found to be a N-terminal amino acid sequence with corresponding homology to β-tubulin (Kirvan et al. 2007 ). Tubulin autoantibodies have also been identified in chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome (Connolly 1997) , Graves' disease and Hashimoto's thyroiditis (Rousset 1983 ).
Purpose of this Study
The purpose of our study was to determine if, and to what extent, the assays of the Cunningham Panel parallel changes in PANDAS/PANS symptoms with treatment. Since immunomodulatory treatment for neuropsychiatric conditions can have positive Kovacevic, Grant, and Swedo 2015) but also variable (Williams et al. 2016 ) outcomes, the ability to predict responsiveness to immunomodulatory treatments would be of high value. As a step towards this goal, this study examines whether the assays within the Cunningham panel are potential biological markers that can be used to follow changes in symptoms with treatment, and could potentially be used to predict response to immunomodulatory treatment. Table 1 Here) first test requisition (Table 1) . Fifty eight of 206 subjects who were identified to have had a Cunningham
(Insert
Panel from April 22, 2013 through Dec. 31, 2016, had two or more panels performed and met the inclusion criteria (see Figure 2 ). Documentation of patient symptoms was received by direct phone and/or email communication with the prescribing clinician or parents, supported by documented call notes in our Laboratory Information Management System (LIMS). Clinician or parent assessments were specific to improvement or non-improvement compared to their initial presentation of symptoms when the first panel was performed. Based upon post-treatment assessments, patients were categorized into one of two groups: Group 1: "Improved/Resolved" (n=34) or Group 2: "Not-Improved/Worsened" (n=24) compared to pre-treatment symptoms. Informed consent/assent was reviewed and approved by the Western Institutional Review Board (WIRB). Since this was a retrospective analysis, parties making assessment were not necessarily blinded to Cunningham Panel results. All patients received medical attention, and 56 of the 58 patients received medications including therapy for infections and/or autoimmune disorders as potential causative factor(s) and/or psychotropic drugs for patient's neuropsychiatric symptoms. Of the two patients who did not receive medications between testing, one patient could not afford IVIg and therefore did not receive medication, and the other patient's medical treatment was watchful waiting or a "tincture of time." (Insert Figure 2) 
Cunningham Panel Assays
Whole blood or serum samples were received according to standard operating procedures, collected in red-top glass tubes without additives (Covidien, Monoject Red Stopper Blood Collection Tube, glass 7 mL draw, part #8881301512). Whole blood was spun to collect serum. Patient serum was tested according to standard operating procedures for Moleculera Labs' CLIA/COLA accredited laboratory (CLIA Number 37D2082408). Assay protocols have been described previously (Cox et al. 2013; Kirvan 2003; Brimberg et al. 2012; . The threshold for a positive response for the four ELISA assays was set at the mean value of normal controls plus two times the standard deviation, followed by J o u r n a l P r e -p r o o f rounding to the nearest titer. In each case, the selected threshold exceeded the 95% confidence interval for the t-distribution. A positive titer result for DR1 is 4000 or higher, for DR2 is 16000 or higher, for lysoganglioside GM1 is 640 or higher, and for tubulin is 2000 or higher. A positive result for CaMKII activation in SK-N-SH cells was set at 130 or ≥30% Since then, additional populations of pediatric controls have been tested with similar results.
Data and methods of analysis
Two distinct approaches were used to evaluate the results of these five assays. The first 
Positive Test Count Score
The Positive Test Count Score is the difference in the number of positive tests pre-treatment, versus the number of positive tests post-treatment in each patient. An increase in the number of positive tests post-treatment results in a negative Positive Test Count Score, an unchanged number results in a score of 0, and a decrease in the number of positive tests results in a positive score. We represent this by the following equation: Positive Test Count Score = (X tub,pre + X d1r,pre + X d2r,pre + X ly so,pre + X CaMKII, pre ) -(X tub,post + X d1r,post + X d2r,post + X ly so,post + X CaMKII, post ) where X = 1 for a positive test and 0 for a negative J o u r n a l P r e -p r o o f
Journal Pre-proof test, the subscripts "tub", "d1r", "d2r", "lyso" and "CaMKII" indicate the assay and the subscripts "pre"
and "post" indicate whether the assay was conducted before or after treatment, respectively.
Magnitude of Change Score
The Magnitude of Change Score examines the magnitude of change in post-treatment test results compared to pre-treatment. This is defined by the equation: Magnitude of Change Score = a 0 + a 1 *DV tub + a 2 *DV d1r + a 3 *DV d2r + a 4 *DV ly so + a 5 *DV CaMKII where DV = log 2 (Titer pos /Titer pre ) for each of the four ELISA assays and DV CaMKII = CaMKII v alue,post -CaMKII v alue,pre for the CaMKII assay. Logistic
Regression Analysis, conducted in R with the glm2 (Fitting Generalized Linear Models) package (version 1.2.1), was used to determine the optimal values of the coefficients a 0 , a 1 , a 2 , a 3 , a 4 and a 5 and the probability of membership in either Group 1 versus Group 2 for each patient.
The value of a 0 , the constant term, and coefficients a 1-5 for tubulin, D1R, D2R, lysoganglioside The resulting logistic regression model is then cross-validated using the "leave one out" method. Note Extensive reproducibility testing was conducted using patient blood samples collected in validated glass tubes without excipients (Red Top glass tubes), and tested repetitively at random intervals over a period of 33 months. The reproducibility testing for D1R is representative of each of these tests. Note that a two-fold dilution scheme is used to determine titers. To assess robustness and ongoing assay reproducibility of the CaMKII assay, routine repeat testing across multiple samples was performed.
Results
Patient Demographics
Patients were either diagnosed with, or suspected of, PANS/PANDAS at the time of their test requisition. All 58 patients presented with various neuropsychiatric symptoms characteristic of the criteria for PANS/PANDAS (Table 1) . Age and gender distribution for all 58 patients at the time of first testing ranged from 2 to 23 years, whereas the mean and median age for patients was 12.2 ± 4.5 and 12.0 years, respectively. The mean time between the first and second Cunningham Panels in Group 1 was 68.1 weeks, versus 66.2 weeks in Group 2 (p=0.87). The median time between tests for these Group 1 was 48 weeks, versus 62 weeks for Group 2. An interesting observation in examining symptom frequency is that patients who improved with therapy (Group 1) had a higher percentage of OCD, behavioral regression and sleep disorders, whereas those that did not improve with therapy (Group 2) had a higher percentage of tic and movement disorders.
(Insert Table 1 Table 2) J o u r n a l P r e -p r o o f
Subjects in Group 1: Improved/Resolved in Symptoms (N=34)
The group of patients reporting symptoms Improved/Resolved post-treatment consisted of 34 individuals ranging in age from 5 to 21 years with a mean age of 12.2 years. There were 13 females (38%) and 21 males (62%). See Table 2 .
Subjects in Group 2: Not Improved/Worsened in Symptoms (N=24)
The group of patients reporting symptoms Not Improved/Worsened consisted of 24 patients ranging in age from 2 years to 23 years with a mean age of 12.1 years. There were 9 females (38%) and 15 males (62%), and there were no statistically significant differences in age or gender between Group 1 and Group 2. There were no statistically significant differences in the time between the first test and the second test in Group 1 versus Group 2 (Table 2) .
Individual Results and Heat Map
The heat-maps (Table 3A and (Insert Table 3A , Table 3B and Table 4 and Figure 3 )
We evaluated the data for any association between changes in Cunningham Panel results and changes in patient symptoms after treatment or medical intervention using two distinct approaches: the Positive Test Count Method and the Magnitude of Change Method. Results from both analyses are J o u r n a l P r e -p r o o f summarized in the 2 x 2 contingency tables for sensitivity, specificity and accuracy ( Figure 4A and 5A) ,
whereas the respective Receiver Operating Characteristic (ROC) curves are shown in Figure 4B and 5B. The dot plots of individual scores by group and by analysis are shown in Figure 4C and 5C.
Positive Test Count Method
This method consists of assessing change in Cunningham Panel results (positive or negative) upon treatment by tallying the number of positive tests for each of the five assays. A 2x2 contingency table analysis (p=5 x 10 -8 , Fisher exact test) revealed an 88% sensitivity, 83% specificity, and an accuracy of 86% ( Figure 4A ).The ROC curve had an AUC of 93.4% ( Figure 4B ). Dot plots of individual scores revealed good separation by group ( Figure 4C ).
In the patients reporting symptom improvement following treatment, 88% ( 
Magnitude of Change Method
Using linear logistic regression we created an optimal function derived from the magnitude of degrees of freedom, respectively. Accordingly, R 2 = 0.62. In contrast to linear regression, R 2 in not related to any correlation coefficient, nor is it a percentage of variance explained by the logistic model, rather it is a ratio indicating how close the fit is to being perfect (R 2 = 1) or the worst possible (R 2 = 0).
As part of characterization of model quality, a summary of the values for all coefficients in "leave one out" analysis are shown in Supplemental Table 1 . The probabilities for the misclassification in the original and leave-on-out validation are given in Supplemental Table 2 .
Results in the 2x2 contingency table (p = 6 x 10 -10 , Fisher exact test) revealed an 88% sensitivity, 91% specificity with an overall accuracy of 90% ( Figure 5A ). Values in 5A are taken from a threshold: 0.522< Probability < 0.557 which provides highest values per the ROC analysis in 5B. For example, if the threshold is set at 0.5, then the number of incorrect assignments of Group 2 to Group 1 increases from 2 to 3 of 24 whereas the number of incorrect assignments of Group 1 to Group 2 is unchanged at 4 of 34 (Supplemental Table 2 ) for an overall accuracy of 88%.The ROC curve used to define the threshold for predicting inclusion in Group 1 or Group 2 resulted in an AUC of 95.7% ( Figure   5B ). Dot plots of individual scores revealed good separation by group ( Figure 5C ). We find that there is good discrimination between Group 1 and Group 2 based on quantitative changes in the test results. Figure 4ABC, Figure 5ABC )
(Insert
There is an interesting trend observed for patients in Group 1; CaMKII values were, more often than not, elevated prior to treatment and then significantly decreased in conjunction with a reduction in symptoms post-treatment (p=0.000004), approaching levels associated with normal control populations ( Figure 6 ). In contrast, those patients in Group 2, defined as those whose symptoms did not improve post-treatment, tended to show elevated CaMKII levels both before and after treatment without any statistically significant change post-treatment (p=0.311) (Figure 7 ).
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Journal Pre-proof (Insert Figure 6 and Figure 7) 
Summary of Treatments and Comparisons between Groups
Retrospective evaluation of treatments revealed that of patients treated with immunotherapy (IVIg, Table 5 ). Note that in general, the utilization frequency of specific treatments is similar between Group 1 and Group 2 ( Table 5 ). The use of "Immunotherapies Only" and "Antimicrobials Only" is somewhat higher in Group 1 than in Group 2, whereas the percentage of patients in Group 2 that received both classes of therapy is somewhat higher than Group 1.
(Insert Table 5 )
Reproducibility of ELISA testing in the Cunningham Panel
For repeated D1R assay we observed 207 readings at the same titer, 62 readings at one titer higher and 75 readings at one titer lower ( Figure 8A ), resulting in a distribution of 17.3%, 61.5% and 21.2%, respectively. No results were greater than one titer dilution away from the peak. When expanded to include mixed patient samples and additionally processed or concentrated patient J o u r n a l P r e -p r o o f samples, we saw rare instances (<0.5%) where the assigned titer was two dilution steps from the peak.
In no cases were any titers greater than two dilution steps from the peak.
Reproducibility of CAMKII assay results in the Cunningham Panel
Seventeen samples underwent repeat CaMKII assay testing. The correlation between the original and the repeat test was 0.90 (p< 1.67x10 -6 ) and the root-mean-square deviation (RMSD) is 13.8 ( Figure 8B ). The deviation (Repeat Assay Value / Original Assay Value) was approximately 15% with no apparent dependence on the actual CaMKII activity over the range of values routinely measured. The baseline value by definition is 100, whereas the threshold for a positive in the CaMKII assay is set at 130 (30% above baseline values defined from measurements in pediatric controls). Figure 8 here) In summary, repetitive testing of multiple samples, multiple times in the ELISA and CaMKII assays using patient samples demonstrates assay robustness and reproducibility.
(Insert
Discussion
For PANDAS and PANS, there is a need to elucidate the pathophysiology and underlying disease mechanisms in order to improve the identification of patients, advance targeted therapies, and to clarify the characteristics of these disorders. The value of identifying a group of biomarkers that correspond to a disease etiology is that it can segment patients exhibiting similar symptoms into groups that can be administered different treatment modalities based upon their underlying disease etiology. In we were able to predict change in symptoms with an accuracy of 90%, sensitivity of 88% and a specificity of 92%.
Comparison with Other Published Studies
In a 2018 study of 80 patients having a diagnosis of ASD, in which 31 children with autoimmune encephalopathy received IVIg treatment, the Cunningham Panel predicted patient improvement and response to IVIg treatment with an accuracy of 81%, a sensitivity of 90% and a specificity of 67% based on the Aberrant Behavior Checklist (ABC) scores; with an accuracy of 88%, a sensitivity of 100% and a specificity of 75% based on the Social Responsiveness Scale (SRS) scores; and with an accuracy of 88% with a sensitivity of 100% and a specificity of 67% based on parental scores (Connery et al. 2018) .
The sensitivity and specificity of the Cunningham Panel in predicting IVIg responsiveness in children with autoimmune encephalopathy and diagnosed with ASD (81% to 88%) are similar to the performance accuracy we observed in this study (87% to 90%). Published literature reveals that children with ASD have strong family histories of immune dysregulation and inflammation, and that the literature supports a strong association of immune dysregulation and ASD (Rossignol and Frye 2012) .
Because current diagnostic criteria for ASD (American Psychiatric Association, DSM-5, 2013) and PANDAS/PANS are based upon clinical symptom clusters , it is possible that a common underlying etiology of these disorders, or a subset of these clinical syndromes, may be immune dysregulation with antineuronal antibodies directed against the basal ganglia and/or other CNS targets in the brain. patient's specimens, and potential direct interference in the assays.
In the referenced study, the authors reported some "healthy controls" showing positive Cunningham Panel results. This could be a result of the invalid collection method or the exclusion and inclusion criteria utilized for their control population (Frye and Shimasaki 2019) . Family history of psychiatric, autoimmune, or movement disorder was not investigated in the controls nor was the history of recent, chronic or recurrent infections. Since PANDAS/PANS is often triggered by an infection which can be subclinical or occult, transient molecular mimicry could have confounded test results. More importantly, although the patients were asked about a psychiatric or autoimmune diagnosis, symptoms of autoimmune or psychiatric disorders were not specifically investigated. This lack of detailed screening of the controls calls into question the extent to which the controls were verified as healthy.
Therapeutic Interventions
Although this current study was not designed as a comparison of treatment interventions, within those whose symptoms improved post-treatment, a greater percentage received some form of immunomodulatory or antimicrobial therapy alone, compared to the patient group whose symptoms did not improve. It was observed that a higher percentage (70.6%) of patients improved who were treated with antimicrobial therapy alone, whereas 52.9% of patients treated with both modalities saw improvement. It is unknown whether those patients who required multiple therapeutic modalities may have had longer duration of illness or greater severity of symptoms. PANDAS/PANS patients typically have undergone multiple symptomatic-focused treatments prior to a recognition of their underlying infectious trigger and autoimmune etiology. It may be that prolonged duration of these conditions prior to proper diagnosis and treatment could impact the outcome of a course of therapy and the treatment duration required to observe symptom resolution in these patients.
J o u r n a l P r e -p r o o f
A confounding issue that could potentially influence the outcome of certain immunomodulatory treatments with IVIg is the observation that in some IVIg lots we tested, we find varying, but significantly elevated levels of antineuronal antibodies against the biological targets and CaMKII activation in the Cunningham Panel (data not shown). Because IVIg is a product produced through the concentration of immunoglobulins from 1,000 or more patients, it would not be unexpected to observe this. However, it
is key that post-treatment testing with the Cunningham Panel be performed after significant clearance of potential exogenous antineuronal antibodies, as this may confound patient results. Estimates of halflife of some manufacturers' IVIg are as long as 40 days in patients (IVIg Manufacturer's Package Insert). Also, in a research setting where testing was performed at regular intervals during immunomodulatory treatment, completely normal testing results have been observed, due to the possibility of immunomodulatory treatment interfering with testing results, either by suppressing the production of these autoantibodies or direct interference. Because of potential for immunomodulatory treatment interference with test results, prescribers are advised to consider waiting at least six to eight weeks or longer following treatment to determine treatment effectiveness in reducing these antineuronal antibodies. Within this study the mean time from pre-treatment testing to post-treatment testing was 68.1 and 66.2 weeks respectively for Group 1 and Group 2.
Future Directions
There is a clear need for more treatment practice guidance for post-infectious autoimmune neuropsychiatric disorders. The recently published treatment guidelines for patients with PANS/PANDAS Thienemann et al. 2017; Frankovich et al. 2017; Cooperstock et al. 2017 ) and clinical and treatment information on the PANDAS Physician Network (PPN) ('PANDAS Physican Network' 2018) will help establish a standard for treatment of these patients. Additionally, in order to help guide treatment decisions, we are systematically analyzing our biobank of over 8,000 annotated samples to study how baseline data may help stratify patient populations into diagnostic subgroups for predicting treatment response.
J o u r n a l P r e -p r o o f
Other clinical reports have been published showing effective utilization of immunomodulatory treatment for autoimmune encephalitis based upon the presence of antineuronal antibodies directed against NMDA receptor (Dalmau, Geis, and Graus 2017) , voltage-gated potassium channel-complex (VGKC) (Vincent et al. 2011) , leucine-rich glioma inactivated-1 (LGI1), astrocyte aquaporin-4 (AQP4) (Zekeridou and Lennon 2015) , glutamic acid decarboxylase (GAD65), gamma-aminobutyric acid-B receptor (GABAB), and others (Mader, Brimberg, and Diamond 2017; Platt, Agalliu, and Cutforth 2017; Mohammad and Dale 2018; Lancaster 2016; Dale, Gorman, and Lim 2017) . It is plausible there could be additional antineuronal antibody targets that lead to symptoms of autoimmune encephalitis.
Interestingly, in a study of 61 patients diagnosed with autoimmune encephalitis by confirmatory testing such as MRI, CSF inflammation, EEG and FDG-PET/CT, it was determined that the anti-neuronal antibodies in this referenced study, such as those listed above, did not account for 48% (29/61) of these patients presenting with autoimmune encephalitis (Probasco et al. 2017) . A future study will include the examination of a broader range of anti-neuronal antibodies. Thus, while there are many known targets for autoantibodies in patients with autoimmune encephalopathies, antibodies to extracellular epitopes of dopamine D2 receptor have also been identified in patients with pediatric basal ganglia encephalitis (Dale et al. 2012 ) a related disorder with overlapping yet distinct clinical presentation to PANDAS/PANS.
Study limitations
Pre-and post-treatment symptom responses were carefully collected and documented by questionnaire and telephone follow-up with parents and physicians. However, because of the lack of a standardized instrument and a single individual assessing symptom severity in all these patients, there could be inter-patient variation in the self-reporting of symptom severity. Future studies would benefit from the utilization of a standardized rating scale in a single study utilizing a single independent assessor for measuring the severity of symptoms. Since PANS/PANDAS is a diagnosis of exclusion and patients currently may not receive this diagnosis during a primary medical visit, patients that are J o u r n a l P r e -p r o o f referred for testing may have visited multiple clinicians and received multiple therapies that have failed prior to their Cunningham Panel. Thus, there might be significant variability between symptom onset and initial testing with the Cunningham panel.
Other limitations to this study include the relatively small sample sizes of patients in each group, which was limited to the numbers of patients that had pre-and post-treatment testing during this interval, and the relatively small number of carefully screened pediatric healthy controls from which the normal or basal levels were obtained.
Although published literature has demonstrated that anti-infectives and immune modulatory therapy can indeed be effective in PANDAS patients (Kovacevic, Grant, and Swedo 2015; , the exact treatment used, dose and duration of treatment and when the treatment was instituted was not controlled as part of this study and could have added to variability.
Interestingly, autoantibodies against certain biomarkers have also been identified in other inflammatory, movement, and/or neuropsychiatric conditions. Although autoantibodies against any individual target may not be diagnostic for PANDAS/PANS or Sydenham's chorea, the entire panel taken together may be a strong aid in a physician's clinical diagnosis of an autoimmune etiology. There also remains the possibility that autoantibodies against these targets may not necessarily be pathogenic but rather an epiphenomena associated with this disorder. Further research and clinical studies are in progress to assess this as a causal contribution or a downstream result of the disorder.
Conclusions
We report here for the first time a strong positive association between the change in anti- These observations and results support a potential common proposed mechanism where infection-triggered immune dysregulation may lead to antineuronal antibodies directed against specific targets in the brain resulting in neuropsychiatric symptoms (Labrie and Brundin 2018) . A Danish study by Köhler-Forsberg et al. of over one million individuals provides compelling epidemiologic evidence that severe infections are linked to the onset of neuropsychiatric illnesses in children (Kohler-Forsberg et al. 2018) . They observed an 8-fold increased risk for obsessive-compulsive disorder in teenagers, and the study identified a 1.5-fold to 5.6-fold elevated risk for neurodevelopmental delay, mental retardation, and behavioral and/or emotional disturbances in the young. If this mechanism proves to be true, there is the potential that subsets of other clinically-defined neuropsychiatric disorders and conditions may have a pathophysiology representing a broader category of disorders referred to as "Autoimmune Encephalopathies of Infectious Etiology," (Figure 9 Graphical Abstract).
In an era of precision medicine, there would be clinical advantages if targeted testing could segment patients having heterogeneous symptoms into discrete groups based upon responsiveness to a particular treatment modality. Although the historical identification of the anti-neuronal antibodies in the Cunningham Panel originated from patients diagnosed with Sydenham chorea and later PANS/PANDAS patients, these biomarker targets may help identify broader populations of patients experiencing neuropsychiatric symptoms triggered by a similar autoimmune etiology that may be responsive to immune modulation therapy. Testing results may also provide a clinician with the biological evidence for the diagnosis of an immune-mediated disorder which may alter their treatment modality.
Based upon this retrospective analysis, there is evidence to support that the Cunningham Panel may have value as an aid in a clinician's diagnosis and management of patients with PANDAS/PANS.
Although it is not clear whether the presence of antineuronal antibodies to these targets may be causal or an associative response to a patient's neuropsychiatric symptoms, identifying such an objective measure is essential for performing future studies on treatment outcomes and to help elucidate a disease mechanism. The results of this study represent a step towards validating antineuronal antibody J o u r n a l P r e -p r o o f tools that may be utilized as an aid in a physician's diagnosis of PANDAS/PANS and support future prospective studies into the understanding of its etiology and pathogenesis. The validation of biological markers may also lead to the identification and development of more efficacious targeted therapeutics for treating patients with these neuropsychiatric disorders. Further, the data generated in this study suggests a larger analysis is warranted including more patients to explore whether baseline data can predict treatment response in patients with neuropsychiatric symptoms. 
Journal of Neuroimmunology
Highlights for article: "Evaluation of the Cunningham Panel™ in Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infection (PANDAS) and Pediatric
